Cargando…

The treatment-related mortality score is associated with non-fatal adverse events following intensive AML induction chemotherapy

Detalles Bibliográficos
Autores principales:	Buckley, S A, Othus, M, Estey, E H, Walter, R B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404219/ https://www.ncbi.nlm.nih.gov/pubmed/25635529 http://dx.doi.org/10.1038/bcj.2014.97

Ejemplares similares

Blast vacuolization in AML patients indicates adverse-risk AML and is associated with impaired survival after intensive induction chemotherapy
por: Ballo, Olivier, et al.
Publicado: (2019)

Regimen‐intensity per count‐recovery and hospitalization index: A new tool to assign regimen intensity for AML
por: Sorror, Mohamed L., et al.
Publicado: (2020)

Prediction of CR following a second course of ‘7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course
por: Othus, M, et al.
Publicado: (2016)

Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy
por: Versluis, Jurjen, et al.
Publicado: (2022)

Improved outcomes with “7+3” induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data
por: Othus, Megan, et al.
Publicado: (2022)

Therapeutic Options for Patients who are not Eligible for Intensive Chemotherapy
por: Estey, Elihu
Publicado: (2013)

Fluid overload is associated with increased 90-day mortality in AML patients undergoing induction chemotherapy
por: Ballo, Olivier, et al.
Publicado: (2021)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events
por: Zhao, Bin, et al.
Publicado: (2018)

P550: INFLUENCE OF RACE ON COMPLICATIONS OF INTENSIVE CHEMOTHERAPY IN AML
por: Abraham, Ivy, et al.
Publicado: (2023)

Phase 1/2 Trial of GCLAM with Dose-Escalated Mitoxantrone for Newly Diagnosed AML or Other High-Grade Myeloid Neoplasms
por: Halpern, Anna B., et al.
Publicado: (2018)

G-CSF-Associated Bone Marrow Necrosis in AML after Induction Chemotherapy
por: Osuorji, Ikenna, et al.
Publicado: (2012)

Early changes in gene expression profiles in AML patients during induction chemotherapy
por: Jakobsen, Ingrid, et al.
Publicado: (2022)

Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center
por: Walter, Roland B., et al.
Publicado: (2014)

Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal
por: Estey, Elihu, et al.
Publicado: (2022)

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
por: Zhao, Bin, et al.
Publicado: (2019)

Diagnostic yield, indications, and outcomes of cranial imaging in AML patients admitted for intensive induction or consolidation chemotherapy: a single-center experience
por: Koschade, Sebastian E., et al.
Publicado: (2023)

Value of ATRIA risk score and gender in predicting adverse events in patients with myocardial infarction
por: Öncel, Can Ramazan
Publicado: (2018)

A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML
por: Gore, Lia, et al.
Publicado: (2017)

Dynamic trajectory of platelet counts after the first cycle of induction chemotherapy in AML patients
por: Bi, Yazhen, et al.
Publicado: (2022)

Fatal Cerebral Events Following Insect Stings May be Due to Inappropriate Mast Cell Activation
por: Khan, Sujoy
Publicado: (2020)

MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT
por: Shukla, Deepak Kumar, et al.
Publicado: (2021)

6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy
por: Wei, Andrew H., et al.
Publicado: (2021)

Lymphocyte Exhaustion in AML Patients and Impacts of HMA/Venetoclax or Intensive Chemotherapy on Their Biology
por: Zhigarev, Dmitry, et al.
Publicado: (2022)

Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy
por: Abbas, Hussein A., et al.
Publicado: (2022)

Rheumatic Immuno-related Adverse Events following Immunotherapy with Checkpoint Inhibitors: Adverse Drug Reaction, or Other?
por: Manzo, Ciro
Publicado: (2021)

Correspondence on Bell’s palsy as an adverse event following COVID-19 vaccination
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML Patients
por: Schnell, Bianca R., et al.
Publicado: (2019)

Correction: Dynamic trajectory of platelet counts after the first cycle of induction chemotherapy in AML patients
por: Bi, Yazhen, et al.
Publicado: (2022)

Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
por: Gyan, Emmanuel, et al.
Publicado: (2022)

Adverse stem cell clones within a single patient’s tumor predict clinical outcome in AML patients
por: Zeller, Christina, et al.
Publicado: (2022)

Response to: Correspondence on Bell’s palsy as an adverse event following COVID-19 vaccination
por: Kim, Sohyeon, et al.
Publicado: (2023)

Fatal Idiopathic Hyperammonemia after Induction Chemotherapy for Acute Myeloid Leukemia
por: Angelo, Christophe, et al.
Publicado: (2020)

New drug approvals in acute myeloid leukemia: what’s the best end point?
por: Estey, E, et al.
Publicado: (2015)

Unique challenges to diagnosing sweet syndrome following induction chemotherapy for relapsed Acute Myeloid Leukemia (AML): A case and brief-review
por: Nazaretyan, Samvel, et al.
Publicado: (2023)

Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML
por: Halpern, Anna B., et al.
Publicado: (2023)

Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML)
por: Acharya, Utkarsh H., et al.
Publicado: (2018)

The impact of adverse events in the intensive care unit on hospital mortality and length of stay
por: Forster, Alan J, et al.
Publicado: (2008)

Relative survival following response to 7+3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes:An analysis of four SWOG studies
por: Othus, Megan, et al.
Publicado: (2018)

DLBCL developed into fatal liver failure during rituximab-containing chemotherapy
por: Shimazu, Yutaka, et al.
Publicado: (2019)

Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy
por: Wei, Andrew H., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0a4hl27o1laro8644jmlmkhuvv